Prevalence and antimicrobial resistance profiles of respiratory microbial flora in African children with HIV-associated chronic lung disease.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
25 Feb 2021
Historique:
received: 29 11 2020
accepted: 12 02 2021
entrez: 26 2 2021
pubmed: 27 2 2021
medline: 20 3 2021
Statut: epublish

Résumé

HIV-associated chronic lung disease (CLD) is common among children living with HIV (CLWH) in sub-Saharan Africa, including those on antiretroviral therapy (ART). However, the pathogenesis of CLD and its possible association with microbial determinants remain poorly understood. We investigated the prevalence, and antibiotic susceptibility of Streptococcus pneumoniae (SP), Staphylococcus aureus (SA), Haemophilus influenzae (HI), and Moraxella catarrhalis (MC) among CLWH (established on ART) who had CLD (CLD+), or not (CLD-) in Zimbabwe and Malawi. Nasopharyngeal swabs (NP) and sputa were collected from CLD+ CLWH (defined as forced-expiratory volume per second z-score < - 1 without reversibility post-bronchodilation with salbutamol), at enrolment as part of a randomised, placebo-controlled trial of azithromycin (BREATHE trial - NCT02426112 ), and from age- and sex-matched CLD- CLWH. Samples were cultured, and antibiotic susceptibility testing was conducted using disk diffusion. Risk factors for bacterial carriage were identified using questionnaires and analysed using multivariate logistic regression. A total of 410 participants (336 CLD+, 74 CLD-) were enrolled (median age, 15 years [IQR = 13-18]). SP and MC carriage in NP were higher in CLD+ than in CLD- children: 46% (154/336) vs. 26% (19/74), p = 0.008; and 14% (49/336) vs. 3% (2/74), p = 0.012, respectively. SP isolates from the NP of CLD+ children were more likely to be non-susceptible to penicillin than those from CLD- children (36% [53/144] vs 11% [2/18], p = 0.036). Methicillin-resistant SA was uncommon [4% (7/195)]. In multivariate analysis, key factors associated with NP bacterial carriage included having CLD (SP: adjusted odds ratio (aOR) 2 [95% CI 1.1-3.9]), younger age (SP: aOR 3.2 [1.8-5.8]), viral load suppression (SP: aOR 0.6 [0.4-1.0], SA: 0.5 [0.3-0.9]), stunting (SP: aOR 1.6 [1.1-2.6]) and male sex (SA: aOR 1.7 [1.0-2.9]). Sputum bacterial carriage was similar in both groups (50%) and was associated with Zimbabwean site (SP: aOR 3.1 [1.4-7.3], SA: 2.1 [1.1-4.2]), being on ART for a longer period (SP: aOR 0.3 [0.1-0.8]), and hot compared to rainy season (SP: aOR 2.3 [1.2-4.4]). CLD+ CLWH were more likely to be colonised by MC and SP, including penicillin-non-susceptible SP strains, than CLD- CLWH. The role of these bacteria in CLD pathogenesis, including the risk of acute exacerbations, should be further studied.

Sections du résumé

BACKGROUND BACKGROUND
HIV-associated chronic lung disease (CLD) is common among children living with HIV (CLWH) in sub-Saharan Africa, including those on antiretroviral therapy (ART). However, the pathogenesis of CLD and its possible association with microbial determinants remain poorly understood. We investigated the prevalence, and antibiotic susceptibility of Streptococcus pneumoniae (SP), Staphylococcus aureus (SA), Haemophilus influenzae (HI), and Moraxella catarrhalis (MC) among CLWH (established on ART) who had CLD (CLD+), or not (CLD-) in Zimbabwe and Malawi.
METHODS METHODS
Nasopharyngeal swabs (NP) and sputa were collected from CLD+ CLWH (defined as forced-expiratory volume per second z-score < - 1 without reversibility post-bronchodilation with salbutamol), at enrolment as part of a randomised, placebo-controlled trial of azithromycin (BREATHE trial - NCT02426112 ), and from age- and sex-matched CLD- CLWH. Samples were cultured, and antibiotic susceptibility testing was conducted using disk diffusion. Risk factors for bacterial carriage were identified using questionnaires and analysed using multivariate logistic regression.
RESULTS RESULTS
A total of 410 participants (336 CLD+, 74 CLD-) were enrolled (median age, 15 years [IQR = 13-18]). SP and MC carriage in NP were higher in CLD+ than in CLD- children: 46% (154/336) vs. 26% (19/74), p = 0.008; and 14% (49/336) vs. 3% (2/74), p = 0.012, respectively. SP isolates from the NP of CLD+ children were more likely to be non-susceptible to penicillin than those from CLD- children (36% [53/144] vs 11% [2/18], p = 0.036). Methicillin-resistant SA was uncommon [4% (7/195)]. In multivariate analysis, key factors associated with NP bacterial carriage included having CLD (SP: adjusted odds ratio (aOR) 2 [95% CI 1.1-3.9]), younger age (SP: aOR 3.2 [1.8-5.8]), viral load suppression (SP: aOR 0.6 [0.4-1.0], SA: 0.5 [0.3-0.9]), stunting (SP: aOR 1.6 [1.1-2.6]) and male sex (SA: aOR 1.7 [1.0-2.9]). Sputum bacterial carriage was similar in both groups (50%) and was associated with Zimbabwean site (SP: aOR 3.1 [1.4-7.3], SA: 2.1 [1.1-4.2]), being on ART for a longer period (SP: aOR 0.3 [0.1-0.8]), and hot compared to rainy season (SP: aOR 2.3 [1.2-4.4]).
CONCLUSIONS CONCLUSIONS
CLD+ CLWH were more likely to be colonised by MC and SP, including penicillin-non-susceptible SP strains, than CLD- CLWH. The role of these bacteria in CLD pathogenesis, including the risk of acute exacerbations, should be further studied.

Identifiants

pubmed: 33632144
doi: 10.1186/s12879-021-05904-3
pii: 10.1186/s12879-021-05904-3
pmc: PMC7908671
doi:

Substances chimiques

Anti-Bacterial Agents 0
Anti-Retroviral Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

216

Subventions

Organisme : Wellcome Trust
ID : 206316/Z/17/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom

Références

J Infect Public Health. 2012 Apr;5(2):133-9
pubmed: 22541259
Clin Infect Dis. 2015 Dec 1;61(11):1708-14
pubmed: 26202769
PLoS One. 2012;7(2):e30787
pubmed: 22363489
PLoS One. 2020 Feb 7;15(2):e0229021
pubmed: 32032364
AIDS. 2016 Nov 28;30(18):2795-2803
pubmed: 27662546
AIDS Rev. 2010 Oct-Dec;12(4):183-94
pubmed: 21179183
S Afr Med J. 2017 Apr 25;107(5):435-439
pubmed: 28492126
Pan Afr Med J. 2017 Feb 02;26:60
pubmed: 28451037
Indian J Pediatr. 2012 Nov;79(11):1447-53
pubmed: 22570015
J Infect Dis. 2006 Aug 1;194(3):385-90
pubmed: 16826488
Pediatrics. 2011 Feb;127(2):e423-41
pubmed: 21262891
Int J Chron Obstruct Pulmon Dis. 2018 Nov 08;13:3663-3667
pubmed: 30510409
J Antimicrob Chemother. 2002 Dec;50 Suppl S2:39-43
pubmed: 12556432
Clin Infect Dis. 2014 Jan;58(2):188-94
pubmed: 24190895
BMC Infect Dis. 2011 Jun 20;11:175
pubmed: 21689403
J Allergy Clin Immunol. 2017 Mar;139(3):977-986.e2
pubmed: 27523432
Trop Med Int Health. 2013 Oct;18(10):1267-8
pubmed: 24016033
Respir Med. 1999 Dec;93(12):845-50
pubmed: 10653044
Int J Tuberc Lung Dis. 2012 Jan;16(1):114-9
pubmed: 22236856
AIDS. 2016 Jun 1;30(9):1327-39
pubmed: 26990629
Clin Infect Dis. 2018 Jan 6;66(2):274-281
pubmed: 29020237
BMC Infect Dis. 2017 Feb 8;17(1):133
pubmed: 28178935
Emerg Infect Dis. 2008 Oct;14(10):1584-91
pubmed: 18826823
J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):275-281
pubmed: 27171738
Microbes Infect. 2009 Apr;11(5):545-53
pubmed: 19306940
J Pediatric Infect Dis Soc. 2016 Jun;5(2):161-9
pubmed: 26407277
PLoS One. 2011 Mar 15;6(3):e17765
pubmed: 21423577
Vaccine. 2018 Nov 19;36(48):7369-7376
pubmed: 30352744
Pneumonia (Nathan). 2018 Jun 25;10:6
pubmed: 29984134
Springerplus. 2016 Jun 24;5(1):877
pubmed: 28443214
J Infect. 2015 Jun;70(6):616-23
pubmed: 25452037
Antimicrob Agents Chemother. 2010 Sep;54(9):3756-62
pubmed: 20585110
Front Microbiol. 2017 Jun 22;8:1163
pubmed: 28690603
Trials. 2017 Dec 28;18(1):622
pubmed: 29282143
Int J Infect Dis. 2012 Oct;16(10):e753-7
pubmed: 22884165
Diagn Microbiol Infect Dis. 2007 Mar;57(3):259-65
pubmed: 17292578
Trop Med Int Health. 2020 May;25(5):590-599
pubmed: 31989731
Trans R Soc Trop Med Hyg. 2019 May 1;113(5):227-233
pubmed: 30624761
Stat Med. 1998 Feb 28;17(4):407-29
pubmed: 9496720
Vaccine. 2013 May 1;31(19):2333-42
pubmed: 23523773
Pediatr Pulmonol. 2008 Jan;43(1):1-10
pubmed: 18041077
Clin Infect Dis. 2012 Jul;55(1):145-52
pubmed: 22474177
BMC Pulm Med. 2020 Feb 28;20(1):56
pubmed: 32111226
BMJ Open. 2020 Dec 2;10(12):e039546
pubmed: 33268410
J Pediatr. 2010 Dec;157(6):1001-5
pubmed: 20656297
Pediatr Infect Dis J. 2006 Sep;25(9):782-90
pubmed: 16940834
Indian J Pediatr. 2011 Apr;78(4):423-9
pubmed: 21165717
Sci Transl Med. 2019 Apr 3;11(486):
pubmed: 30944164
Pediatr Pulmonol. 2019 Nov;54(11):1765-1773
pubmed: 31338996
J Med Microbiol. 2012 May;61(Pt 5):678-685
pubmed: 22282460
Pediatr Infect Dis J. 2008 Jan;27(1):59-64
pubmed: 18162940
Expert Rev Vaccines. 2019 Oct;18(10):1069-1089
pubmed: 31585049
Hum Vaccin Immunother. 2016;12(2):314-25
pubmed: 26317537
AIDS. 2005 Jul 1;19(10):1035-42
pubmed: 15958834
PLoS One. 2015 Jul 01;10(7):e0129649
pubmed: 26132206
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Vaccine. 2007 Mar 22;25(13):2458-64
pubmed: 17030494
PLoS One. 2018 May 10;13(5):e0196722
pubmed: 29746496
Nat Rev Microbiol. 2017 Oct 12;15(11):675-687
pubmed: 29021598
Sci Rep. 2015 Jun 12;5:11344
pubmed: 26067932

Auteurs

Regina E Abotsi (RE)

Department of Molecular and Cell Biology & Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa. abtreg001@myuct.ac.za.
Department of Pharmaceutical Microbiology, School of Pharmacy, University of Health and Allied Sciences, Ho, Ghana. abtreg001@myuct.ac.za.

Mark P Nicol (MP)

Division of Infection and Immunity, School of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Western Australia, Perth, Australia.

Grace McHugh (G)

Biomedical Research and Training Institute, Harare, Zimbabwe.

Victoria Simms (V)

MRC International Statistics & Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.

Andrea M Rehman (AM)

MRC International Statistics & Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.

Charmaine Barthus (C)

Division of Medical Microbiology, University of Cape Town, Cape Town, South Africa.

Slindile Mbhele (S)

Division of Medical Microbiology, University of Cape Town, Cape Town, South Africa.

Brewster W Moyo (BW)

Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.

Lucky G Ngwira (LG)

Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
Liverpool School of Tropical Medicine, Liverpool, UK.

Hilda Mujuru (H)

Department of Paediatrics, University of Zimbabwe, Harare, Zimbabwe.

Beauty Makamure (B)

Biomedical Research and Training Institute, Harare, Zimbabwe.

Justin Mayini (J)

Biomedical Research and Training Institute, Harare, Zimbabwe.

Jon Ø Odland (JØ)

Department of Community Medicine, University of Tromsø, Tromsø, Norway.
International Research Laboratory for Reproductive Ecotoxicology, The National Research University Higher School of Economics, Moscow, Russia.
School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.

Rashida A Ferrand (RA)

Biomedical Research and Training Institute, Harare, Zimbabwe.
Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK.

Felix S Dube (FS)

Department of Molecular and Cell Biology & Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH